Could a common antibiotic cure a parasitic skin disease?
NCT ID NCT06798402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether injecting the antibiotic ciprofloxacin directly into skin sores caused by leishmaniasis works as well as the standard treatment, sodium stibogluconate. Eighty people with one to seven sores will be randomly assigned to receive weekly injections of one drug or the other. The sores will be monitored for up to 90 days to see which treatment leads to better healing.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ciprofloxacin (an antibiotic) and sodium stibogluconate (a standard anti-parasitic drug)
- What this could lead to
- If ciprofloxacin works as well as the standard treatment, it could offer a more widely available and cheaper option for treating cutaneous leishmaniasis.
- What could go wrong
- This is a small, early-phase trial with only 80 participants. Ciprofloxacin may not be as effective as the standard drug, and results may not apply to all types of leishmaniasis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Nov 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis Exclusion Criteria: * Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study * patients on prolonged corticosteroid therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutaneous leishmaniasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mustansiriyah University
RECRUITINGBaghdad, 10047, Iraq
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heat treatment could bring leishmaniasis care to local clinics
- AI app aims to help frontline workers diagnose neglected skin diseases
- New rapid test could speed up diagnosis of parasitic skin disease
- Scientists study leishmania infections to improve diagnosis and care
- Antibiotic injections show promise for parasitic skin sores
- Could a gel heal parasite skin sores? new study begins